Reid Laurence
Insider CIK 1492749 · ALNY SVP, Chief Business Officer · KALV Director · DBTX See Remarks, Director · MGX Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| MGX Metagenomi Therapeutics, I | P Buy | 2026-09-09 | 2026-09-11 | 117 | $1.18 | $138 | 20,000 | SEC↗ |
| MGX Metagenomi Therapeutics, I | P Buy | 2026-09-09 | 2026-09-11 | 19,883 | $1.17 | $23.3K | 19,883 | SEC↗ |
| MGX Metagenomi Therapeutics, I | P Buy | 2026-09-09 | 2026-09-11 | 117 | $1.18 | $138 | 20,000 | SEC↗ |
| MGX Metagenomi Therapeutics, I | P Buy | 2026-09-09 | 2026-09-11 | 19,883 | $1.17 | $23.3K | 19,883 | SEC↗ |
| KALV KalVista Pharmaceuticals, | D To issuer deriv | 2026-06-11 | 2026-06-11 | 17,000 | — | $0 | 0 | SEC↗ |
| MGX Metagenomi Therapeutics, I | A Award deriv | 2026-06-09 | 2026-06-11 | 17,400 | — | $0 | 17,400 | SEC↗ |
| MGX Metagenomi, Inc. | A Award deriv | 2025-09-02 | 2025-09-02 | 42,000 | — | $0 | 42,000 | SEC↗ |
| KALV KalVista Pharmaceuticals, | A Award deriv | 2024-11-23 | 2024-11-26 | 17,000 | — | $0 | 17,000 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | D To issuer deriv | 2023-09-25 | 2023-09-25 | 72,000 | — | $0 | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | D To issuer deriv | 2023-09-25 | 2023-09-25 | 187,500 | — | $0 | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | D To issuer deriv | 2023-09-25 | 2023-09-25 | 1,072,539 | — | $0 | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | D To issuer | 2023-09-25 | 2023-09-25 | 220,849 | — | $0 | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | A Award deriv | 2023-03-16 | 2023-03-17 | 72,000 | — | $0 | 72,000 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | A Award | 2023-03-16 | 2023-03-17 | 195,000 | — | $0 | 220,849 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | A Award deriv | 2022-02-25 | 2022-02-28 | 187,500 | — | $0 | 187,500 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | P Buy | 2021-09-15 | 2021-09-17 | 10,000 | $7.64 | $76.4K | 25,849 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-12-31 | 2015-01-05 | 17,000 | — | $0 | 133,609 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | F Tax w/h | 2014-12-31 | 2015-01-05 | 2,802 | $97.00 | $271.8K | 18,103 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-12-31 | 2015-01-05 | 17,000 | $15.99 | $271.8K | 20,905 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | A Award deriv | 2014-12-12 | 2014-12-16 | 6,667 | — | $0 | 6,667 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-11-18 | 2014-11-19 | 3,639 | — | $0 | 150,609 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-11-18 | 2014-11-19 | 2,500 | — | $0 | 12,500 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-11-18 | 2014-11-19 | 3,861 | — | $0 | 1,728 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-11-18 | 2014-11-19 | 3,639 | $15.99 | $58.2K | 13,905 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-11-18 | 2014-11-19 | 4,485 | $91.08 | $408.5K | 4,007 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-11-18 | 2014-11-19 | 5,413 | $90.30 | $488.8K | 8,492 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-11-18 | 2014-11-19 | 102 | $91.79 | $9.4K | 3,905 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-11-18 | 2014-11-19 | 3,861 | $9.14 | $35.3K | 10,266 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-11-18 | 2014-11-19 | 2,500 | $7.10 | $17.8K | 6,405 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-08-18 | 2014-08-20 | 2,500 | — | $0 | 15,000 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-08-18 | 2014-08-20 | 11,000 | — | $0 | 5,589 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-08-18 | 2014-08-20 | 6,500 | $66.83 | $434.4K | 10,905 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-08-18 | 2014-08-20 | 2,500 | $7.10 | $17.8K | 6,405 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-08-18 | 2014-08-20 | 7,000 | $67.80 | $474.6K | 3,905 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-08-18 | 2014-08-20 | 11,000 | $9.14 | $100.5K | 17,405 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-05-19 | 2014-05-21 | 2,500 | — | $0 | 17,500 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-05-19 | 2014-05-21 | 11,000 | — | $0 | 16,589 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-05-19 | 2014-05-21 | 10,900 | $58.01 | $632.3K | 3,905 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-05-19 | 2014-05-21 | 2,600 | $57.07 | $148.4K | 14,805 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-05-19 | 2014-05-21 | 11,000 | $9.14 | $100.5K | 17,405 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-05-19 | 2014-05-21 | 2,500 | $7.10 | $17.8K | 6,405 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-02-19 | 2014-02-20 | 3,500 | — | $0 | 154,248 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2014-02-19 | 2014-02-20 | 10,000 | — | $0 | 20,000 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-02-19 | 2014-02-20 | 400 | $81.45 | $32.6K | 3,905 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-02-19 | 2014-02-20 | 3,079 | $78.62 | $242.1K | 21,226 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-02-19 | 2014-02-20 | 11,465 | $80.02 | $917.4K | 9,761 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2014-02-19 | 2014-02-20 | 5,456 | $80.85 | $441.1K | 4,305 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-02-19 | 2014-02-20 | 3,500 | $15.99 | $56.0K | 24,305 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2014-02-19 | 2014-02-20 | 10,000 | $7.10 | $71.0K | 20,805 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | F Tax w/h | 2014-01-23 | 2014-01-27 | 3,698 | $89.49 | $330.9K | 10,805 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2013-12-30 | 2014-01-02 | 3,752 | — | $0 | 157,748 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | F Tax w/h | 2013-12-30 | 2014-01-02 | 930 | $64.51 | $60.0K | 14,503 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2013-12-30 | 2014-01-02 | 3,752 | $15.99 | $60.0K | 15,433 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | A Award deriv | 2013-12-18 | 2013-12-18 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2013-11-13 | 2013-11-15 | 13,500 | — | $0 | 161,500 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2013-11-13 | 2013-11-15 | 13,500 | $15.99 | $215.9K | 25,181 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2013-11-13 | 2013-11-15 | 13,500 | $53.36 | $720.4K | 11,681 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2013-05-28 | 2013-05-30 | 5,000 | — | $0 | 30,000 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2013-05-28 | 2013-05-30 | 5,000 | $7.10 | $35.5K | 16,681 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2013-05-28 | 2013-05-30 | 5,000 | $30.00 | $150.0K | 11,681 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise deriv | 2013-02-08 | 2013-02-12 | 5,000 | — | $0 | 35,000 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | S Sale | 2013-02-08 | 2013-02-12 | 5,000 | $25.00 | $125.0K | 11,681 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | M Exercise | 2013-02-08 | 2013-02-12 | 5,000 | $7.10 | $35.5K | 16,681 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | A Award deriv | 2012-12-20 | 2012-12-21 | 40,000 | — | $0 | 40,000 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | P Buy | 2012-02-21 | 2012-02-23 | 930 | $10.75 | $10.0K | 11,681 | SEC↗ |
| ALNY ALNYLAM PHARMACEUTICALS, I | A Award | 2012-01-23 | 2012-01-25 | 10,751 | — | $0 | 10,751 | SEC↗ |